TEI 3356 | 133906-74-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: TEI 3356
• 英文别名: (1S,5S,6R,7R)-5-[7-hydroxy-6-[3(S)-hydroxy-3-methyl-1(E)-octenyl]bicyclo[3.3.0]oct-2-ene-3-yl]pentanoic acid；(1S,5S,6R,7R)-3-(4-carboxybutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene；5-(-7-Hydroxy-6-(4-hydroxy-4-methyl-1-octenyl)bicyclo(3.3.0)oct-2-en-3-yl)pentanoic acid；5-[(3aS,5R,6R,6aS)-5-hydroxy-6-[(E,4S)-4-hydroxy-4-methyloct-1-enyl]-1,3a,4,5,6,6a-hexahydropentalen-2-yl]pentanoic acid
• CAS: 133906-74-8
• 化学式: C₂₂H₃₆O₄
• 分子量: 364.525
• InChiKey: WJDXRLOGFZXXNY-OFYJTPHNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  26
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N,N'-羰基二咪唑 、 TEI 3356 在 ammonium hydroxide 、 potassium hydrogen sulphate 作用下， 以 水 为溶剂， 以40%的产率得到(1S,5S,6R,7R)-3-(4-carbamoylbutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
  参考文献：
  名称：

  NEUROPATHY IMPROVERS CONTAINING NITROGENOUS COMPOUNDS AS THE ACTIVE INGREDIENT

  摘要：

  公开号：

  EP1201235B1

文献信息

• REMEDIES FOR ALLERGIC DISEASES
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1563845A1

  公开（公告）日：2005-08-17

  The present invention relates to a prophylactic and/or therapeutic agent for an allergic disease which contains a compound having an agonistic activity to EP3 receptor that is one of the prostaglandin E2 receptor subtypes. More specifically, a compound having an agonistic activity to EP3 receptor is effective in therapy of an allergic respiratory disease such as bronchial asthma, pediatric asthma, allergic asthma, or atopic asthma, and a selective agonistic compound can be expected to induce a more remarkable therapeutic effect.

  本发明涉及一种预防和/或治疗过敏性疾病的药物，它含有一种对前列腺素 E2 受体亚型之一的 EP3 受体具有激动活性的化合物。更具体地说，对EP3受体具有激动活性的化合物可有效治疗过敏性呼吸道疾病，如支气管哮喘、小儿哮喘、过敏性哮喘或特应性哮喘，选择性激动化合物可望引起更显著的治疗效果。
• REMEDY FOR CARTILAGE-RELATED DISEASES
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1661580A1

  公开（公告）日：2006-05-31

  The present invention relates an agent for treating cartilage-related disease comprising as an active ingredient a substance having an EP2 and/or EP3 agonist activity. A substance having an agonist activity to EP2 and/or EP3 has effects of stimulating chondrogenesis, stimulating chondrocyte growth, stimulating chondrocyte differentiation, inhibiting cartilage calcification and inhibiting cartilage degradation, or effects of stimulating integrin mRNA expression, stimulating fibronectin mRNA expression, stimulating D1 mRNA expression and inhibiting osteopontin mRNA expression, and, therefore, is useful as an agent for treating cartilage-related disease.

  本发明涉及一种治疗软骨相关疾病的制剂，其活性成分包括一种具有 EP2 和/或 EP3 激动剂活性的物质。具有 EP2 和/或 EP3 激动剂活性的物质具有刺激软骨生成、刺激软骨细胞生长、刺激软骨细胞分化、抑制软骨钙化和抑制软骨降解的作用，或具有刺激整合素 mRNA 表达、刺激纤连蛋白 mRNA 表达、刺激 D1 mRNA 表达和抑制骨生成素 mRNA 表达的作用，因此可用作治疗软骨相关疾病的制剂。
• Remedy for cartilage-related diseases
  申请人：Ono Pharmaceutical Co., Ltd.

  公开号：EP2422814A1

  公开（公告）日：2012-02-29

  A remedy for cartilage-related diseases containing as the active ingredient a substance having an agonistic activity to EP2 and/or EP3. A substance having an agonistic activity to EP2 and/or EP3 has effects of promoting chondrogenesis, promoting chondrocyte growth, promoting chondrocyte differentiation, inhibiting cartilage calcification and inhibiting cartilage degradation, or effects of promoting integrin mRNA expression, promoting fibronectin mRNA expression, promoting cyclin D1 mRNA expression and inhibiting osteopontin mRNA expression, and therefore, is useful as a remedy for cartilage-related diseases.

  一种治疗软骨相关疾病的药物，其活性成分含有一种对 EP2 和/或 EP3 具有激动活性的物质。对 EP2 和/或 EP3 具有激动活性的物质具有促进软骨生成、促进软骨细胞生长、促进软骨细胞分化、抑制软骨钙化和抑制软骨降解的作用，或具有促进整合素 mRNA 表达、促进纤连蛋白 mRNA 表达、促进细胞周期蛋白 D1 mRNA 表达和抑制骨生成素 mRNA 表达的作用，因此可作为软骨相关疾病的治疗药物。
• Remedies for allergic diseases
  申请人：Narumiya Shuh

  公开号：US20060128810A1

  公开（公告）日：2006-06-15

  The present invention relates to a prophylactic and/or therapeutic agent for an allergic disease which contains a compound having an agonistic activity to EP3 receptor that is one of the prostaglandin E2 receptor subtypes. More specifically, a compound having an agonistic activity to EP3 receptor is effective in therapy of an allergic respiratory disease such as bronchial asthma, pediatric asthma, allergic asthma, or atopic asthma, and a selective agonistic compound can be expected to induce a more remarkable therapeutic effect.

  本发明涉及一种预防和/或治疗过敏性疾病的药物，它含有一种对前列腺素 E2 受体亚型之一的 EP3 受体具有激动活性的化合物。更具体地说，对EP3受体具有激动活性的化合物可有效治疗过敏性呼吸道疾病，如支气管哮喘、小儿哮喘、过敏性哮喘或特应性哮喘，选择性激动化合物可望引起更显著的治疗效果。
• Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels
  申请人：Herlands Louis

  公开号：US20070026079A1

  公开（公告）日：2007-02-01

  Provided are methods of increasing K ATP channel activity in the hypothalamus of a mammal, methods of reducing glucose production in a mammal, methods of reducing peripheral glucose levels in a mammal, methods of reducing triglyceride levels in a mammal, methods of reducing very low density lipoprotein (VLDL) levels in a mammal, methods of methods of reducing gluconeogenesis in the liver of a mammal, methods of treating metabolic disorders such as diabetes, hyperglycemia, insulin resistance, glucose intolerance, metabolic syndrome and/or obesity, and methods of increasing glucose production and peripheral glucose levels in a mammal. Also provided are methods of treating heart failure, ischemia, coronary heart disease, familial lipoprotein lipase deficiency, hypopituitarism, hyperlipidemia, hypertriglyceridemia, hyperVLDLemia, atherosclerosis, hypercholesterolemia, hypertension, polycystic ovary syndrome, gonadotropin deficiency and/or amenorrhea.